These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

659 related items for PubMed ID: 17086563

  • 1. Use of cyclo-oxygenase 2 inhibitors (COX-2) and prescription non-steroidal anti-inflammatory drugs (NSAIDS) in UK and USA populations. Implications for COX-2 cardiovascular profile.
    Arellano FM, Yood MU, Wentworth CE, Oliveria SA, Rivero E, Verma A, Rothman KJ.
    Pharmacoepidemiol Drug Saf; 2006 Dec; 15(12):861-72. PubMed ID: 17086563
    [Abstract] [Full Text] [Related]

  • 2. Gastrointestinal and cardiovascular risk of non-selective NSAIDs and COX-2 inhibitors in elderly patients with knee osteoarthritis.
    Turajane T, Wongbunnak R, Patcharatrakul T, Ratansumawong K, Poigampetch Y, Songpatanasilp T.
    J Med Assoc Thai; 2009 Dec; 92 Suppl 6():S19-26. PubMed ID: 20128070
    [Abstract] [Full Text] [Related]

  • 3. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation.
    Chen YF, Jobanputra P, Barton P, Bryan S, Fry-Smith A, Harris G, Taylor RS.
    Health Technol Assess; 2008 Apr; 12(11):1-278, iii. PubMed ID: 18405470
    [Abstract] [Full Text] [Related]

  • 4. The balance between severe cardiovascular and gastrointestinal events among users of selective and non-selective non-steroidal anti-inflammatory drugs.
    van der Linden MW, van der Bij S, Welsing P, Kuipers EJ, Herings RM.
    Ann Rheum Dis; 2009 May; 68(5):668-73. PubMed ID: 18495734
    [Abstract] [Full Text] [Related]

  • 5. Evaluation of risk profiles for gastrointestinal and cardiovascular adverse effects in nonselective NSAID and COX-2 inhibitor users: a cohort study using pharmacy dispensing data in The Netherlands.
    Layton D, Souverein PC, Heerdink ER, Shakir SA, Egberts AC.
    Drug Saf; 2008 May; 31(2):143-58. PubMed ID: 18217790
    [Abstract] [Full Text] [Related]

  • 6. Comparison of the baseline cardiovascular risk profile among hypertensive patients prescribed COX-2-specific inhibitors or nonspecific NSAIDs: data from real-life practice.
    Zhao SZ, Burke TA, Whelton A, von Allmen H, Henderson SC.
    Am J Manag Care; 2002 Oct; 8(15 Suppl):S392-400. PubMed ID: 12416789
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Use of nonsteroidal anti-inflammatory drugs and gastroprotective agents before the advent of cyclooxygenase-2-selective inhibitors: analysis of a large United States claims database.
    Schnitzer TJ, Kong SX, Mavros PP, Straus WL, Watson DJ.
    Clin Ther; 2001 Dec; 23(12):1984-98. PubMed ID: 11813933
    [Abstract] [Full Text] [Related]

  • 9. A regional audit of the use of COX-2 selective non-steroidal anti-inflammatory drugs (NSAIDs) in rheumatology clinics in the West Midlands, in relation to NICE guidelines.
    Price-Forbes AN, Callaghan R, Allen ME, Rowe IF.
    Rheumatology (Oxford); 2005 Jul; 44(7):921-4. PubMed ID: 15827035
    [Abstract] [Full Text] [Related]

  • 10. Initiation of antihypertensive therapy among new users of cyclooxygenase-2-selective and nonselective NSAIDs.
    Langman MJ, Eichler HG, Mavros P, Watson DJ, Kong SX.
    Int J Clin Pharmacol Ther; 2004 May; 42(5):260-6. PubMed ID: 15176648
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Cardiovascular and gastrointestinal toxicity of selective cyclo-oxygenase-2 inhibitors in man.
    Dajani EZ, Islam K.
    J Physiol Pharmacol; 2008 Aug; 59 Suppl 2():117-33. PubMed ID: 18812633
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study.
    Rahme E, Nedjar H.
    Rheumatology (Oxford); 2007 Mar; 46(3):435-8. PubMed ID: 17255138
    [Abstract] [Full Text] [Related]

  • 15. Non-steroidal anti-inflammatory drug-induced cardiovascular adverse events: a meta-analysis.
    Gunter BR, Butler KA, Wallace RL, Smith SM, Harirforoosh S.
    J Clin Pharm Ther; 2017 Feb; 42(1):27-38. PubMed ID: 28019014
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Blood pressure destabilization and related healthcare utilization among hypertensive patients using nonspecific NSAIDs and COX-2-specific inhibitors.
    Zhao SZ, Burke TA, Whelton A, von Allmen H, Henderson SC.
    Am J Manag Care; 2002 Oct; 8(15 Suppl):S401-13. PubMed ID: 12416790
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. [Further definition of the role of COX-2 inhibitors and NSAIDs in patients with nociceptive pain].
    Bijlsma JW, Lems WF, van de Laar MA.
    Ned Tijdschr Geneeskd; 2007 Apr 07; 151(14):795-8. PubMed ID: 17469317
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.